NCT03871959 - Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2019

Primary Completion Date

May 30, 2022

Study Completion Date

June 8, 2022

Conditions

Adenocarcinoma of the PancreasAdenocarcinoma of the ColonAdenocarcinoma of the Rectum

Interventions

DRUG

Pembrolizumab

200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.

DRUG

DEBIO1143

3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.

Trial Locations (1)

Centre Léon Bérard, Lyon